This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hammond, L. A. Articles by Rowinsky, E. K. Search for Related Content PubMed PubMed Citation Articles by Hammond, L. A. Articles by Rowinsky, E. K. Social Bookmarking                            What's this?

Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies

From the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio; The University of Texas Health Science Center at San Antonio, San Antonio; Division of Oncology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX; and Schering-Plough Research Institute, Kenilworth, NJ.

Address reprint requests to Lisa A. Hammond, MD, The Institute for Drug Development, Cancer Therapy and Research Center, 8122 Datapoint Dr, Suite 650, San Antonio, TX 78229; email lhammond@ saci.org.

PURPOSE: To determine the principal toxicities, characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of temozolomide (TMZ) on a daily-for-5-days schedule, and recommend a dose for subsequent disease-directed studies in both minimally pretreated (MP) and heavily pretreated (HP) patients.

PATIENTS AND METHODS: Patients received TMZ as a single oral dose daily for 5 consecutive days every 28 days. TMZ doses were escalated from 100 to 150, and 150 to 200 mg/m²/d in separate cohorts of MP and HP patients. PK plasma was sampled on days 1 and 5. TMZ concentrations were analyzed and pertinent PK parameters were related to the principal toxicities of TMZ in PD analyses.

RESULTS: Twenty-four patients were treated with 85 courses of TMZ. Thrombocytopenia and neutropenia were the principal dose-limiting toxicities (DLTs) of TMZ on this schedule. The cumulative rate of severe myelosuppressive effects was unacceptably high at TMZ doses exceeding 150 mg/m²/d in both MP and HP patients. TMZ was absorbed rapidly with maximum concentrations achieved in 0.90 hours, on average, and elimination was rapid, with a half-life and systemic clearance rate (Cl_S/F) averaging 1.8 hours and 115 mL/min/m², respectively. When clearance was normalized to body-surface area (BSA), interpatient variability in Cl_S/F was reduced from 20% to 13% on day 1 and from 16% to 10% on day 5. Patients who experienced DLT had significantly higher maximum drug concentration (median 16 v 9.5 µg/mL, P = .0084) and area under the concentration-time curve (median 36 v 23 µg-h/mL, P = .0019) values on day 5.

CONCLUSION: Prior myelosuppressive therapy was not a determinant of toxicity. TMZ 150 mg/m²/d administered as a single oral dose daily for 5 days every 4 weeks is well tolerated by MP and HP patients, with higher doses resulting in unacceptably high rates of severe hematologic toxicity. TMZ doses should be individualized according to BSA rather than use of a prespecified oral dose for all individuals. TMZ is an optimal agent to develop in combination with other cytotoxic, biologic, and targeted therapeutics for patients with relevant malignancies.

Presented in part at the Thirty-First Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 20-23, 1995.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Rosso, C. S. Brock, J. M. Gallo, A. Saleem, P. M. Price, F. E. Turkheimer, and E. O. Aboagye A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients Cancer Res., January 1, 2009; 69(1): 120 - 127. [Abstract] [Full Text] [PDF]

				T. M. Horton, P. A. Thompson, S. L. Berg, P. C. Adamson, A. M. Ingle, M. E. Dolan, S. M. Delaney, M. Hedge, H. L. Weiss, M.-F. Wu, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study J. Clin. Oncol., November 1, 2007; 25(31): 4922 - 4928. [Abstract] [Full Text] [PDF]

				H. Rubie, J. Chisholm, A. S. Defachelles, B. Morland, C. Munzer, D. Valteau-Couanet, V. Mosseri, C. Bergeron, C. Weston, C. Coze, et al. Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group New Agents Group Study J. Clin. Oncol., November 20, 2006; 24(33): 5259 - 5264. [Abstract] [Full Text] [PDF]

				J. P. Fruehauf, H. Brem, S. Brem, A. Sloan, G. Barger, W. Huang, and R. Parker In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas Clin. Cancer Res., August 1, 2006; 12(15): 4523 - 4532. [Abstract] [Full Text] [PDF]

				A. M. Fontes, B. M. Davis, L. P. Encell, K. Lingas, D. T. Covas, M. A. Zago, L. A. Loeb, A. E. Pegg, and S. L. Gerson Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells Mol. Cancer Ther., January 1, 2006; 5(1): 121 - 128. [Abstract] [Full Text] [PDF]

				K. E. Warren, A. A. Aikin, M. Libucha, B. C. Widemann, E. Fox, R. J. Packer, and F. M. Balis Phase I Study of O6-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors J. Clin. Oncol., October 20, 2005; 23(30): 7646 - 7653. [Abstract] [Full Text] [PDF]

				B. Yamini, X. Yu, G. Y. Gillespie, D. W. Kufe, and R. R. Weichselbaum Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor {alpha} by Temozolomide in Experimental Glioblastoma Cancer Res., September 15, 2004; 64(18): 6381 - 6384. [Abstract] [Full Text] [PDF]

				L. A. Hammond, J. R. Eckardt, J. G. Kuhn, S. L. Gerson, T. Johnson, L. Smith, R. L. Drengler, E. Campbell, G. R. Weiss, D. D. Von Hoff, et al. A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms Clin. Cancer Res., March 1, 2004; 10(5): 1645 - 1656. [Abstract] [Full Text] [PDF]

				A. C. Lockhart, M. Howard, K. R. Hande, B. J. Roth, J. D. Berlin, F. Vreeland, A. Campbell, E. Fontana, F. Fiorentini, C. Fowst, et al. A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors Clin. Cancer Res., January 15, 2004; 10(2): 468 - 475. [Abstract] [Full Text] [PDF]

				K. Vera, L. Djafari, S. Faivre, J.-S. Guillamo, K. Djazouli, M. Osorio, F. Parker, C. Cioloca, B. Abdulkarim, J.-P. Armand, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors Ann. Onc., January 1, 2004; 15(1): 161 - 171. [Abstract] [Full Text] [PDF]

				D. A. Persons, E. R. Allay, N. Sawai, P. W. Hargrove, T. P. Brent, H. Hanawa, A. W. Nienhuis, and B. P. Sorrentino Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells Blood, July 15, 2003; 102(2): 506 - 513. [Abstract] [Full Text] [PDF]

				B. L. Ebert, E. Niemierko, K. Shaffer, and R. Salgia Use of Temozolomide with Other Cytotoxic Chemotherapy in the Treatment of Patients with Recurrent Brain Metastases from Lung Cancer Oncologist, February 1, 2003; 8(1): 69 - 75. [Abstract] [Full Text] [PDF]

				S. D. Baker, J. Verweij, E. K. Rowinsky, R. C. Donehower, J. H. M. Schellens, L. B. Grochow, and A. Sparreboom Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001 J Natl Cancer Inst, December 18, 2002; 94(24): 1883 - 1888. [Abstract] [Full Text] [PDF]

				S. Gururangan, I. Cokgor, J. N. Rich, S. Edwards, M. L. Affronti, J. A. Quinn, J. E. Herndon II, J. M. Provenzale, R. E. McLendon, S. Tourt-Uhlig, et al. Phase I study of GliadelTM wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas Neuro-oncol, October 1, 2001; 3(4): 246 - 250. [Abstract] [PDF]

				T. P. Spiro, L. Liu, S. Majka, J. Haaga, J. K. V. Willson, and S. L. Gerson Temozolomide: The Effect of Once- and Twice-a-Day Dosing on Tumor Tissue Levels of the DNA Repair Protein O6-Alkylguanine-DNA-Alkyltransferase Clin. Cancer Res., August 1, 2001; 7(8): 2309 - 2317. [Abstract] [Full Text] [PDF]

				K. Ochs and B. Kaina Apoptosis Induced by DNA Damage O -Methylguanine Is Bcl-2 and Caspase-9/3 Regulated and Fas/Caspase-8 Independent Cancer Res., October 1, 2000; 60(20): 5815 - 5824. [Abstract] [Full Text]

				H. S. Friedman, T. Kerby, and H. Calvert Temozolomide and Treatment of Malignant Glioma Clin. Cancer Res., July 1, 2000; 6(7): 2585 - 2597. [Abstract] [Full Text]